MarketPeel
Pricing
…
RR

Robin Shane Readnour

ANTX
DIRECTOR · AN2 THERAPEUTICS, INC. · CIK 0001914883
FILING MIX · LIFETIME70%/30%
BUYS
28
SELLS
12
TOTAL VALUE
$3.03M
COMPANIES
1
ACTIVE SINCE
Mar 2022
HOLDINGS NOW
633,867
AVG SELL PX
$8.01
TRADE KIND
SHOWING 40 / 40
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
20 backtested trades · 8 horizons · 14 pendingHow are these numbers computed? →
Forward-return performance of every backtestable P/S trade by Robin Shane Readnour, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d20+60.00%+2.50%+0.32%+2.18%+1.40%—
14d20+60.00%+3.37%+0.24%+3.13%-0.89%—
30d20+50.00%-7.92%-0.29%-7.62%-2.99%—
60d20+30.00%-25.07%+0.98%-26.05%-16.94%—
90d20+30.00%-28.28%-0.91%-27.37%-16.98%—
180d20+30.00%-29.33%+1.30%-30.63%-16.68%—
1y20+30.00%-34.83%+13.13%-47.96%-36.75%—
2y20(14 pending)+66.67%-88.89%+37.67%-126.56%-141.73%—
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
ANTX · 633,867 shares · as of Aug 17, 2026
0163,143326,287489,430652,5732023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
2026
FLOW · 28 buys / 12 sellsCOVERAGE · 19 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
ANTX
AN2 THERAPEUTICS, INC.
SALE
18,706$6.01$112.4K633,867Aug 17, 2026Aug 19, 2026 ↗View →
ANTX
AN2 THERAPEUTICS, INC.
SALE
16,696$6.01$100.3K565,592Aug 17, 2026Aug 19, 2026 ↗View →
ANTX
AN2 THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
20,724——20,724Mar 19, 2026Mar 23, 2026 ↗View →
ANTX
AN2 THERAPEUTICS, INC.
SALE
20,724——0Mar 19, 2026Mar 23, 2026 ↗View →
ANTX
AN2 THERAPEUTICS, INC.
SALE
23,742——0Mar 19, 2026Mar 23, 2026 ↗View →
ANTX
AN2 THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
23,742——23,742Mar 19, 2026Mar 23, 2026 ↗View →
ANTX
AN2 THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
20,400——20,400Feb 20, 2026Feb 23, 2026 ↗View →
ANTX
AN2 THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
19,111——19,111May 22, 2025May 23, 2025 ↗View →
ANTX
AN2 THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
9,077——9,077Dec 19, 2024Dec 23, 2024 ↗View →
ANTX
AN2 THERAPEUTICS, INC.
PURCHASE
5,000$1.49$7.5K652,573Dec 10, 2024Dec 10, 2024 ↗View →
ANTX
AN2 THERAPEUTICS, INC.
PURCHASE
5,000$1.49$7.5K582,288Dec 10, 2024Dec 10, 2024 ↗View →
ANTX
AN2 THERAPEUTICS, INC.
PURCHASE
12,289$1.43$17.6K577,288Dec 9, 2024Dec 10, 2024 ↗View →
ANTX
AN2 THERAPEUTICS, INC.
PURCHASE
18,483$1.43$26.4K647,573Dec 9, 2024Dec 10, 2024 ↗View →
ANTX
AN2 THERAPEUTICS, INC.
PURCHASE
12,711$1.45$18.4K564,999Dec 6, 2024Dec 10, 2024 ↗View →
ANTX
AN2 THERAPEUTICS, INC.
PURCHASE
6,517$1.45$9.4K629,090Dec 6, 2024Dec 10, 2024 ↗View →
ANTX
AN2 THERAPEUTICS, INC.
PURCHASE
25,000$1.42$35.4K552,288Nov 27, 2024Nov 27, 2024 ↗View →
ANTX
AN2 THERAPEUTICS, INC.
PURCHASE
25,000$1.42$35.4K622,573Nov 27, 2024Nov 27, 2024 ↗View →
ANTX
AN2 THERAPEUTICS, INC.
PURCHASE
12,500$1.39$17.4K527,288Nov 26, 2024Nov 27, 2024 ↗View →
ANTX
AN2 THERAPEUTICS, INC.
PURCHASE
12,500$1.39$17.4K597,573Nov 26, 2024Nov 27, 2024 ↗View →
ANTX
AN2 THERAPEUTICS, INC.
PURCHASE
25,000$1.15$28.9K514,788Nov 20, 2024Nov 21, 2024 ↗View →
ANTX
AN2 THERAPEUTICS, INC.
PURCHASE
25,000$1.16$29.0K585,073Nov 20, 2024Nov 21, 2024 ↗View →
ANTX
AN2 THERAPEUTICS, INC.
PURCHASE
75,000$1.04$77.7K489,788Nov 19, 2024Nov 21, 2024 ↗View →
ANTX
AN2 THERAPEUTICS, INC.
PURCHASE
75,000$1.03$77.5K560,073Nov 19, 2024Nov 21, 2024 ↗View →
ANTX
AN2 THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
64,503——64,503Jun 19, 2024Jun 21, 2024 ↗View →
ANTX
AN2 THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
719$21.91$15.8K485,073Jan 12, 2024Jan 17, 2024 ↗View →
ANTX
AN2 THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
706$21.92$15.5K414,788Jan 12, 2024Jan 17, 2024 ↗View →
ANTX
AN2 THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
1,800$21.92$39.5K485,792Jan 10, 2024Jan 12, 2024 ↗View →
ANTX
AN2 THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
1,869$21.93$41.0K415,494Jan 10, 2024Jan 12, 2024 ↗View →
ANTX
AN2 THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
23,742——23,742Jun 7, 2023Jun 9, 2023 ↗View →
ANTX
AN2 THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
20,724——20,724May 12, 2022May 16, 2022 ↗View →
ANTX
AN2 THERAPEUTICS, INC.
PURCHASE
71,839——404,974Mar 29, 2022Mar 31, 2022 ↗View →
ANTX
AN2 THERAPEUTICS, INC.
SALE
71,839——0Mar 29, 2022Mar 31, 2022 ↗View →
ANTX
AN2 THERAPEUTICS, INC.
PURCHASE
333,135——333,135Mar 29, 2022Mar 31, 2022 ↗View →
ANTX
AN2 THERAPEUTICS, INC.
SALE
333,135——0Mar 29, 2022Mar 31, 2022 ↗View →
ANTX
AN2 THERAPEUTICS, INC.
PURCHASE
61,491——346,647Mar 29, 2022Mar 31, 2022 ↗View →
ANTX
AN2 THERAPEUTICS, INC.
SALE
61,491——0Mar 29, 2022Mar 31, 2022 ↗View →
ANTX
AN2 THERAPEUTICS, INC.
PURCHASE
285,156——285,156Mar 29, 2022Mar 31, 2022 ↗View →
ANTX
AN2 THERAPEUTICS, INC.
SALE
285,156——0Mar 29, 2022Mar 31, 2022 ↗View →
ANTX
AN2 THERAPEUTICS, INC.
PURCHASE
70,716$15.00$1.06M417,363Mar 29, 2022Mar 31, 2022 ↗View →
ANTX
AN2 THERAPEUTICS, INC.
PURCHASE
82,618$15.00$1.24M487,592Mar 29, 2022Mar 31, 2022 ↗View →
Other insiders · ANTX
Loading peer insiders…
About this filer
CIK 0001914883
ROLE
Director
PRIMARY
ANTX
COMPANIES
1
ACTIVE SINCE
Mar 2022
MARKETPEEL · /INSIDER/0001914883DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback